The effects of CDK4/6 inhibitors on chemotherapy-induced senescent cells
To investigate the effects of abemaciclib (a CDK4/6 inhibitor) on the secretory phenotype (SASP) and other characteristics of chemotherapy-induced senescent cells, we performed single-cell RNA sequencing on vehicle-treated proliferating BJ fibroblasts, doxorubicin-induced senescent cells, and doxorubicin-induced senescent cells treated with abemaciclib. This approach also enables the resolution of cellular heterogeneity among senescent cells induced by the same stimulus—a level of detail that cannot be captured with bulk RNA sequencing.
To investigate the effects of abemaciclib (a CDK4/6 inhibitor) on the secretory phenotype (SASP) and other characteristics of chemotherapy-induced senescent cells, we performed single-cell RNA sequencing on vehicle-treated proliferating BJ fibroblasts, doxorubicin-induced senescent cells, and doxorubicin-induced senescent cells treated with abemaciclib. This approach also enables the resolution of cellular heterogeneity among senescent cells induced by the same stimulus—a level of detail that cannot be captured with bulk RNA sequencing.
European Bioinformatics Institute